Why it matters
This policy statement from the American Academy of Pediatrics is one of the most important documents in the whole landscape of trans youth healthcare, and I come back to it often. The AAP is not a fringe body. It is the professional home of paediatricians across the United States, and when it publishes a policy statement, that statement shapes clinical practice, insurance coverage, school policy, and the arguments made in courts. This one was published in 2018, reaffirmed in August 2023, and it comes down clearly and without hedging on the side of gender-affirming care.
The finding I hear quoted most often, and the one I think matters most in conversations with families, is the one about parental support and suicide risk. A study of 433 transgender adolescents in Ontario found suicide attempt rates of 4% among those with strongly supportive parents, and as high as 60% among those whose parents were not supportive. I want to sit with that gap for a moment, because it is not a statistical footnote. It is the difference between a child who survives adolescence and one who may not. Parental support is not a nice-to-have. It is, according to this evidence, one of the most powerful factors in whether a trans young person lives.
The statement is equally direct on what the mental health difficulties trans young people face actually come from. There is no evidence, the AAP states, that risk for mental illness is inherently attributable to a transgender or gender-diverse identity. The distress is multifactorial, rooted in stigma, discrimination, social rejection, and limited access to competent care, not in being trans. The American Psychiatric Association made the same point in 2012, and the AAP cites it here: being transgender 'implies no impairment in judgment, stability, reliability, or general social or vocational capabilities.' Mental illness is not the identity. It is what happens when the world responds to that identity with hostility.
On the question of children's capacity to know their own gender, the statement is equally firm. Prepubertal children who assert a transgender identity know their gender as clearly and consistently as their cisgender peers. The old 'watchful waiting' approach, holding a child's stated identity as possibly true until some arbitrary point, often after puberty has already begun, is named here as outdated, and the AAP explains exactly why: it withholds support from a child who needs it, it pathologises gender diversity and fluidity, and it was built on early studies with methodological flaws and limited follow-up. More recent research points in the opposite direction: valuing a child for who they are, rather than who they might become, fosters secure attachment and resilience.
For families asking whether social affirmation is safe, the statement offers one of the most practically useful findings in the whole document. Children who socially affirm their gender and are supported in doing so show no increase in depression and only minimal, clinically insignificant increases in anxiety compared with age-matched averages. That is a striking result, and it directly challenges the framing that allowing a child to use a different name or wear different clothes is somehow risky or premature.
On puberty blockers, the AAP describes gonadotrophin-releasing hormone analogues as reversible: if treatment is stopped, endogenous puberty resumes. The available data, it states, show that pubertal suppression generally leads to improved psychological functioning in adolescence and young adulthood. The statement acknowledges areas where long-term research remains limited, bone metabolism, fertility effects when suppression is followed by hormone therapy, and I think that honesty is part of what makes it a credible document rather than a promotional one.
The recommendations section asks for insurance coverage of gender-affirming care, integration of trans health into medical education, safe school environments, and legal protections. None of this is fringe. All of it follows directly from the evidence the statement presents.
What it doesn't claim
The AAP is careful to note that this policy statement is not a comprehensive clinical guide. It draws on available research and expert opinion to set a framework for paediatricians, rather than prescribing specific clinical protocols for each intervention. The authors acknowledge that research on appropriate clinical management is limited by insufficient funding, a point worth remembering when critics demand a level of evidence that the field has been systematically underfunded to produce.
On puberty blockers specifically, the statement names genuinely uncertain areas: long-term effects on bone mineral density and on fertility when suppression is followed directly by cross-sex hormone therapy without endogenous puberty occurring. These are real uncertainties, not invented ones, and the AAP states them plainly. Acknowledging them does not undercut the central finding that pubertal suppression generally improves psychological outcomes; it simply tells clinicians and families where ongoing monitoring and conversation are important.
The epidemiological figures cited, approximately 0.7% of youth aged 13 to 17 identifying as transgender, around 150,000 people, are extrapolations from adult data collected in 2014, and the statement notes that there have been no large-scale prevalence studies among children and adolescents. The figure is likely an underestimate given stigma and the difficulty of capturing the full range of gender-diverse identities.
The statement also acknowledges that the evidence base for some aspects of affirmative care was described as 'limited but growing' at the time of publication. That was in 2018. The body of evidence has continued to grow since, which is part of why the AAP reaffirmed the statement in 2023 rather than retiring it.
If there is a paper that you would like me to review, just let Sammy know.
Reviewed by Dr Helen Webberley, Gender Specialist and founder of GenderGP.